Results 111 to 120 of about 50,558 (217)

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences

, 2017
Objective: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ...
Jason Seet, Janet Wu, Alice Tseng, Elizabeth J. Phillips, Christine A. Hughes   +4 more
core   +2 more sources

Reply to the Letter by Mazzitelli M. et al. Regarding “Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase”

Cancer Medicine, Volume 15, Issue 10, October 2026.
Daniele Caracciolo, Pierfrancesco Tassone, Pierosandro Tagliaferri   +2 more
wiley   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

, 2018
Background: Concerns have been voiced over the capacity of deintensification strategies to preserve neurocognitive function and prevent neurocognitive impairment. Methods: We present the 96 week results of a neurocognitive substudy nested within the SALT
Pérez Valero, Ignacio, Rubio García, Rafael, PérezMolina, José Antonio   +2 more
core   +1 more source

Letter to the Editor Regarding “Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase”

Cancer Medicine, Volume 15, Issue 10, October 2026.
Maria Mazzitelli, Pierluigi Del Vecchio, Jon Salmanton‐García, Antonella Cingolani, Livio Pagano, Carlo Torti   +5 more
wiley   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, Volume 117, Issue 4, Page 922-935, October 2026.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

Characteristics and management of low‐level viraemia in people living with HIV in a resource‐limited setting: A multicentre retrospective study in Greece

HIV Medicine, Volume 27, Issue 10, Page 1663-1669, October 2026.
Abstract Objectives Low‐level viraemia (LLV) persists in some people living with HIV despite antiretroviral therapy, raising concerns about virologic failure. We assessed the characteristics, management and outcomes of LLV in Greece, where next‐generation sequencing, therapeutic drug monitoring and electronic adherence monitoring are unavailable ...
Lydia Leonidou, Giota Lourida, Konstantinos Protopapas, Charalampos D. Moschopoulos, Dimitrios Zoulas, Charisis Totsikas, Dimitrios Basoulis, Elpida Mastrogianni, Apostolos Beloukas, Maria Lagadinou, Markos Marangos, Vasileios Papastamopoulos, Antonios Papadopoulos, Mina Psichogiou   +13 more
wiley   +1 more source

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response

Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson, Sebastiano Barbieri, Andrey Verich, Elise Tu, Andrew Lloyd, Gregory J. Dore, Gail V. Matthews, Marianne Martinello   +7 more
wiley   +1 more source

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

Infection and Drug Resistance
Na Chen,1,2 Xuben Yu,3 Lu Li,1 Ping Yang,1 Rong Dong,1,4 Yizhen Huang,1,5 Xiao Ling,1,6 Qiaoqiao Shentu,1,7 Wenqiao Yu,8 Saiping Jiang1 1Department of Clinical Pharmaceutical, The First Affiliated Hospital of Zhejiang University School of Medicine ...
Chen N, Yu X, Li L, Yang P, Dong R, Huang Y, Ling X, Shentu Q, Yu W, Jiang S   +9 more
doaj  

Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2)

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin, Clémence Ramier, Cécile Brouard, Vincent Di Beo, Yoann Allier, Abbas Mourad, Morgane Bureau‐Stoltmann, Philippe Sogni, Sylvie Deuffic‐Burban, Patrizia Carrieri, Benjamin Rolland, Marc Bourliere, Camelia Protopopescu   +12 more
wiley   +1 more source